Feature | December 06, 2013

Stroke Mortality is Down, but the Reason Remains a Mystery

stroke treatment devices clinical trial study alabama
December 6, 2013 — A national group of leading scientists, including one University of Alabama at Birmingham (UAB) expert, said that for more than 100 years, fewer people have been dying of stroke, yet it is still unclear why this decline remains constant.
 
The American Heart Assn. (AHA) and American Stroke Assn. have published a scientific statement, “Factors Influencing the Decline in Stroke Mortality,” which has also been affirmed by the American Academy of Neurology as an educational tool for neurologists. The statement is published in the AHA journal Stroke.
 
Stroke is a leading cause of long-term disability and was previously recognized as the third leading cause of death in the United States, according to the National Stroke Association. However, stroke has now fallen to the fourth leading cause of death due to decreases in people dying from it. This has led the Centers for Disease Control and Prevention to acknowledge the decline and a similar decline in heart disease as one of the 10 great achievements in public health of the 20th century.
 
George Howard, Dr.P.H., professor, department of Biostatistics, School of Public Health, UAB, and statement co-author explained that, even with these dramatic decreases, there is still more to be done.
 
“Stroke has been declining since 1900, and this could be a result of changes leading to fewer people having a stroke or because people are less likely to die after they have a stroke,” said Howard. “Nobody really knows why, but several things seem to be contributing to fewer deaths from stroke.”
 
Perhaps the biggest contributor to the decline, Howard said, are changes leading to lower blood pressure levels, which is the biggest of the stroke risk factors. Other contributors may include reductions in smoking, better treatment of cholesterol and how people are cared for after having a stroke.
 
“We don’t know how much all of the sources are contributing,” said Howard. “Certainly, we want it to keep going down; but if we don’t understand why the numbers are decreasing, we can’t work toward that trend.”
 
Howard said that, in the last 11 years, stroke deaths have declined by 30 percent.
 
“It’s a big deal, so you could argue that our battle is won,” he said. “But I think we still have a lot to be accomplished in this area.”
 
Andrei Alexandrov, M.D., professor of neurology and director, UAB Comprehensive Stroke Center, was not affiliated with the statement but said it brings welcome news.
 
“This likely is attributable not only to better arterial blood pressure control over recent years, but also to a greater number of neurological specialists focused on stroke care across many hospitals in the United States and abroad,” said Alexandrov. “Better early stroke recognition and specialized care can also reduce the risk of dying from stroke.”
 
Alexandrov pointed out one finding of the statement — the lower death rate among adults younger than 65 years of age — deserves further attention since a large proportion of stroke victims in the Southeastern United States are young.
 
“More efforts are needed to reduce mortality and prevent first-ever stroke incidence, as well as to reverse disability following stroke by improving patient access to hospitals providing clot-busting therapy,” said Alexandrov.
 
Howard agrees that, while stroke prevention and care have played a large part in the decline of stroke mortality, more research needs to be done in stroke prevention.
 
“This brings up an interesting question: should more research resources go toward areas where we’ve seen success, or should they go where differences haven’t been made yet?” said Howard. “I’d say there’s an argument for both.”
 
For more information: www.uab.edu

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init